查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387501

Omega-3处方药市场报告：2030 年趋势、预测与竞争分析

Omega 3 Prescription Drug Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

Omega-3处方药趋势与预测

到 2030 年，全球Omega-3处方药市场预计将达到 48 亿美元，2024 年至 2030 年年复合成长率为 8.5%。这个市场的主要驱动因素是高三酸甘油脂血症、肥胖、心血管疾病 (CVD)比例的上升，以及人们对维持胆固醇水平的意识不断增强，市场参与者希望治疗相关的医疗问题。我们专注于创造创新药物。全球Omega-3处方药市场的未来前景广阔，高三酸甘油脂血症、高高胆固醇症发炎性肠道疾病、发炎性肠道疾病、类风湿性关节炎、精神疾病和神经发育障碍市场存在机会。

Omega-3处方药市场洞察

Lucintel 预测，由于 Vascepa 的广泛接受度，在预测期内仍将是最大的细分市场。

由于该地区对心臟相关疾病的担忧不断增加，预计北美在预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球Omega-3处方药市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球Omega-3处方药市场趋势（2018-2023）与预测（2024-2030）
  • 按药品分類的全球Omega-3处方药市场
    • Vascepa
    • Lovaza
    • 其他的
  • 按配销通路的全球Omega-3处方药市场
    • 医院药房
    • 零售药房
    • 线上药房
  • 全球Omega-3处方药市场（按应用）
    • 高三酸甘油脂血症
    • 高胆固醇
    • 发炎性肠道疾病
    • 类风湿性关节炎
    • 精神疾病
    • 神经发育障碍
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球Omega-3处方药市场（按地区）
  • 北美Omega-3处方药市场
  • 欧洲Omega-3处方药市场
  • 亚太地区Omega-3处方药市场
  • 其他地区Omega-3处方药市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球Omega-3处方药市场成长机会（依药品划分）
    • 全球Omega-3处方药市场成长机会（依配销通路）
    • 全球Omega-3处方药市场成长机会（按应用）
    • 全球Omega-3处方药市场成长机会（按地区）
  • 全球Omega-3处方药市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球Omega-3处方药市场产能
    • 全球Omega-3处方药市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Abbott
  • Amarin Pharmaceuticals
  • GSK
  • Natrapharm
  • Viatris
  • Grupo Ferrer Internacional
  • Camber Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Zydus
  • Hikma Pharmaceuticals
简介目录

Omega 3 Prescription Drug Trends and Forecast

The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets. The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 8.5% from 2024 to 2030. The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

A more than 150-page report is developed to help in your business decisions.

Omega 3 Prescription Drug by Segment

The study includes a forecast for the global omega 3 prescription drug by drug, distribution channel, application, and region.

Omega 3 Prescription Drug Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Vascepa
  • Lovaza
  • Others

Omega 3 Prescription Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Omega 3 Prescription Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypertriglyceridemia
  • High Cholesterol
  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis
  • Mental Health Conditions
  • Neurodevelopmental Disorders
  • Others

Omega 3 Prescription Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Omega 3 Prescription Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies omega 3 prescription drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the omega 3 prescription drug companies profiled in this report include-

  • Abbott
  • Amarin Pharmaceuticals
  • GSK
  • Natrapharm
  • Viatris
  • Grupo Ferrer Internacional
  • Camber Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Zydus
  • Hikma Pharmaceuticals

Omega 3 Prescription Drug Market Insights

Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Features of the Global Omega 3 Prescription Drug Market

Market Size Estimates: Omega 3 prescription drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Omega 3 prescription drug market size by drug, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Omega 3 prescription drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug, distribution channel, application, and regions for the omega 3 prescription drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the omega 3 prescription drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the omega 3 prescription drug market size?

Answer: The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030.

Q2. What is the growth forecast for omega 3 prescription drug market?

Answer: The global omega 3 prescription drug market is expected to grow with a CAGR of 8.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the omega 3 prescription drug market?

Answer: The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

Q4. What are the major segments for omega 3 prescription drug market?

Answer: The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets.

Q5. Who are the key omega 3 prescription drug market companies?

Answer: Some of the key omega 3 prescription drug companies are as follows:

  • Abbott
  • Amarin Pharmaceuticals
  • GSK
  • Natrapharm
  • Viatris
  • Grupo Ferrer Internacional
  • Camber Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Zydus
  • Hikma Pharmaceuticals

Q6. Which omega 3 prescription drug market segment will be the largest in future?

Answer: Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

Q7. In omega 3 prescription drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the omega 3 prescription drug market by drug (vascepa, lovaza, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Omega 3 Prescription Drug Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Omega 3 Prescription Drug Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Omega 3 Prescription Drug Market by Drug
    • 3.3.1: Vascepa
    • 3.3.2: Lovaza
    • 3.3.3: Others
  • 3.4: Global Omega 3 Prescription Drug Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Online Pharmacy
  • 3.5: Global Omega 3 Prescription Drug Market by Application
    • 3.5.1: Hypertriglyceridemia
    • 3.5.2: High Cholesterol
    • 3.5.3: Inflammatory Bowel Disease
    • 3.5.4: Rheumatoid Arthritis
    • 3.5.5: Mental Health Conditions
    • 3.5.6: Neurodevelopmental Disorders
    • 3.5.7: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Omega 3 Prescription Drug Market by Region
  • 4.2: North American Omega 3 Prescription Drug Market
    • 4.2.2: North American Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
  • 4.3: European Omega 3 Prescription Drug Market
    • 4.3.1: European Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
    • 4.3.2: European Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
  • 4.4: APAC Omega 3 Prescription Drug Market
    • 4.4.1: APAC Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
    • 4.4.2: APAC Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
  • 4.5: ROW Omega 3 Prescription Drug Market
    • 4.5.1: ROW Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
    • 4.5.2: ROW Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Drug
    • 6.1.2: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Application
    • 6.1.4: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Region
  • 6.2: Emerging Trends in the Global Omega 3 Prescription Drug Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Omega 3 Prescription Drug Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Omega 3 Prescription Drug Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott
  • 7.2: Amarin Pharmaceuticals
  • 7.3: GSK
  • 7.4: Natrapharm
  • 7.5: Viatris
  • 7.6: Grupo Ferrer Internacional
  • 7.7: Camber Pharmaceuticals
  • 7.8: Dr. Reddy's Laboratories
  • 7.9: Zydus
  • 7.10: Hikma Pharmaceuticals